抗埃博拉病毒感染的治疗策略。
Therapeutic Strategies against Ebola Virus Infection.
机构信息
Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
出版信息
Viruses. 2022 Mar 11;14(3):579. doi: 10.3390/v14030579.
Abstract
Since the 2014-2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. This review aims to highlight potential EBOV therapeutics and their target(s) of inhibition, serving as a summary of the literature to inform readers of the novel candidates available in the continued search for EBOV antivirals.
摘要
自 2014-2016 年疫情以来，埃博拉病毒（EBOV）已传播到多个国家，成为全球健康的主要威胁。EBOV 是风险组 4 病原体，这给针对该病毒的对策的发展带来了重大障碍。人们一直在努力开发抗 EBOV 的免疫和治疗方法，近年来有三种疫苗和两种基于抗体的治疗方法获得批准。尽管如此，埃博拉病毒病的高死亡率突出表明，需要不断开发抗病毒策略，以结合疫苗接种计划，为未来的 EBOV 爆发管理做好准备。本综述旨在强调潜在的 EBOV 疗法及其抑制的靶标，作为文献综述，为读者提供在继续寻找 EBOV 抗病毒药物时可获得的新型候选药物的信息。
相似文献
1
Therapeutic Strategies against Ebola Virus Infection.抗埃博拉病毒感染的治疗策略。
Viruses. 2022 Mar 11;14(3):579. doi: 10.3390/v14030579.
2
Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.设计和开发针对埃博拉病毒的疫苗、药物和疗法的进展。
Front Immunol. 2018 Aug 10;9:1803. doi: 10.3389/fimmu.2018.01803. eCollection 2018.
3
Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.埃博拉病毒感染治疗方法的最新进展。
Recent Adv Antiinfect Drug Discov. 2024;19(4):276-299. doi: 10.2174/0127724344267452231206061944.
4
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.基于痘病毒的埃博拉病毒表达 GP 和 VP40 蛋白疫苗候选物的免疫原性和疗效的差异。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.
5
The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.用于治疗埃博拉病毒感染的药物靶点和抗病毒分子
Curr Top Med Chem. 2017;17(3):361-370. doi: 10.2174/1568026616666160829161318.
6
Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.表达埃博拉病毒糖蛋白的重组水疱性口炎病毒（rVSV-EBOV），一种新的埃博拉疫苗。
Drugs Today (Barc). 2021 Jan;57(1):27-45. doi: 10.1358/dot.2021.57.1.3233361.
7
Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.马源免疫球蛋白片段可保护非人灵长类动物免受埃博拉病毒病的侵害。
J Virol. 2019 Feb 19;93(5). doi: 10.1128/JVI.01548-18. Print 2019 Mar 1.
8
Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies.埃博拉病毒检测：一种在疫苗诱导抗体存在的情况下用于埃博拉病毒感染和监测的差分血清诊断检测方法。
EBioMedicine. 2022 Aug;82:104186. doi: 10.1016/j.ebiom.2022.104186. Epub 2022 Jul 25.
9
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.VSV-EBOV 疫苗接种诱导的抗病毒先天免疫反应有助于快速保护。
mBio. 2019 May 28;10(3):e00597-19. doi: 10.1128/mBio.00597-19.
10
[Overview of Ebola virus vaccine].[埃博拉病毒疫苗概述]
Sheng Wu Gong Cheng Xue Bao. 2015 Jan;31(1):1-23.
引用本文的文献
1
Direct Intercellular Transport Mode of Filovirus Nucleocapsids.丝状病毒核衣壳的直接细胞间运输模式
Int J Mol Sci. 2025 Sep 1;26(17):8485. doi: 10.3390/ijms26178485.
2
Development of health emergency response capability evaluation framework for primary health institutions in metropolis: based on Delphi method and analytic hierarchy process.基于德尔菲法和层次分析法的大城市基层医疗卫生机构卫生应急能力评价框架构建
Front Public Health. 2025 Jul 23;13:1577853. doi: 10.3389/fpubh.2025.1577853. eCollection 2025.
3
Development of a Novel, Highly Sensitive System for Evaluating Ebola Virus Particle Formation.用于评估埃博拉病毒颗粒形成的新型高灵敏度系统的开发。
Viruses. 2025 Jul 19;17(7):1016. doi: 10.3390/v17071016.
4
Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus.瑞德西韦、mAb114、REGN-EB3和ZMapp可部分挽救感染低代次基奎特埃博拉病毒变种的非人灵长类动物。
Nat Commun. 2025 Apr 23;16(1):3824. doi: 10.1038/s41467-025-59168-5.
5
Structural basis for Ebola virus nucleocapsid assembly and function regulated by VP24.由VP24调控的埃博拉病毒核衣壳组装及功能的结构基础
Nat Commun. 2025 Mar 10;16(1):2171. doi: 10.1038/s41467-025-57236-4.
6
RNA structure: implications in viral infections and neurodegenerative diseases.RNA结构：对病毒感染和神经退行性疾病的影响
Adv Biotechnol (Singap). 2024 Feb 2;2(1):3. doi: 10.1007/s44307-024-00010-2.
7
Guardians at the Gate: Optimization of Small Molecule Entry Inhibitors of Ebola and Marburg Viruses.关卡守护者：埃博拉病毒和马尔堡病毒小分子进入抑制剂的优化
J Med Chem. 2025 Jan 9;68(1):135-155. doi: 10.1021/acs.jmedchem.4c01646. Epub 2024 Dec 16.
8
Hepatic and pulmonary macrophage activity in a mucosal challenge model of Ebola virus disease.埃博拉病毒病黏膜激发模型中的肝脏和肺部巨噬细胞活性
Front Immunol. 2024 Nov 20;15:1439971. doi: 10.3389/fimmu.2024.1439971. eCollection 2024.
9
Discovery of Thiophene Derivatives as Potent, Orally Bioavailable, and Blood-Brain Barrier-Permeable Ebola Virus Entry Inhibitors.发现噻吩衍生物作为有效的、口服生物利用度和血脑屏障渗透性的埃博拉病毒进入抑制剂。
J Med Chem. 2024 Sep 26;67(18):16381-16402. doi: 10.1021/acs.jmedchem.4c01267. Epub 2024 Sep 9.
10
Serologic, Virologic and Pathologic Features of Cats with Naturally Occurring Feline Infectious Peritonitis Enrolled in Antiviral Clinical Trials.在抗病毒临床试验中纳入的自然感染猫传染性腹膜炎猫的血清学、病毒学和病理学特征。
Viruses. 2024 Mar 17;16(3):462. doi: 10.3390/v16030462.
本文引用的文献
1
Current state of Ebola virus vaccines: A snapshot.埃博拉病毒疫苗的现状：简要概述
PLoS Pathog. 2021 Dec 9;17(12):e1010078. doi: 10.1371/journal.ppat.1010078. eCollection 2021 Dec.
2
Quercetin Blocks Ebola Virus Infection by Counteracting the VP24 Interferon-Inhibitory Function.槲皮素通过拮抗 VP24 的干扰素抑制功能阻断埃博拉病毒感染。
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00530-20.
3
Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors.从接种疫苗的供体中分离出针对埃博拉病毒的强效中和单克隆抗体。
MAbs. 2020 Jan-Dec;12(1):1742457. doi: 10.1080/19420862.2020.1742457.
4
Serine-Arginine Protein Kinase 1 Regulates Ebola Virus Transcription.丝氨酸-精氨酸蛋白激酶 1 调节埃博拉病毒转录。
mBio. 2020 Feb 25;11(1):e02565-19. doi: 10.1128/mBio.02565-19.
5
Ebola virus disease.埃博拉病毒病。
Nat Rev Dis Primers. 2020 Feb 20;6(1):13. doi: 10.1038/s41572-020-0147-3.
6
Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.治疗性抗体鸡尾酒分析揭示了协同和广谱埃博拉病毒中和的决定因素。
Immunity. 2020 Feb 18;52(2):388-403.e12. doi: 10.1016/j.immuni.2020.01.001. Epub 2020 Feb 4.
7
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities.组合筛选一组经 FDA 批准的药物，鉴定出具有抗埃博拉病毒活性的几种候选药物。
Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. doi: 10.1016/j.bbrc.2019.11.065. Epub 2019 Dec 2.
8
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
9
Discovery of sclareol and sclareolide as filovirus entry inhibitors.发现硬尾醇和硬尾醇内酯作为丝状病毒进入抑制剂。
J Asian Nat Prod Res. 2020 May;22(5):464-473. doi: 10.1080/10286020.2019.1681407. Epub 2019 Nov 18.
10
Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24.基于药物信息学的埃博拉病毒蛋白 VP24 潜在生物活性化合物的鉴定。
Comput Biol Med. 2019 Oct;113:103414. doi: 10.1016/j.compbiomed.2019.103414. Epub 2019 Aug 28.
Zotero 插件